新型口服抗凝药在心血管病中的研究进展

发布时间：2018-06-11 22:41

本文选题：新型口服抗凝药 + 心血管病　；参考：《重庆医科大学》2016年硕士论文

【摘要】：新型口服抗凝药包括直接凝血酶抑制剂和Xa因子抑制剂,直接凝血酶抑制剂有达比加群,Xa因子抑制剂则包括利伐沙班、阿哌沙班、依度沙班,其具有较好的有效性和安全性、口服便利、起效快、食品药物影响小、无需常规监测凝血象等优点。在心血管病方面,利伐沙班等药物已被批准用于房颤的卒中预防和静脉血栓的治疗中。然而,新型抗凝剂在急性冠脉综合征中的应用,还仍处于临床试验阶段。新型口服抗凝药也具有一定局限性,包括半衰期短、缺乏抗凝效果监测方法、无药物相关性出血的特效拮抗剂等,同时,在肝肾功能不全、癌症、妊娠等特殊人群中的使用安全性仍缺乏大量临床数据。在此,笔者对新型口服抗凝药在心血管病中的研究进展进行综述。
[Abstract]:The new oral anticoagulants include direct thrombin inhibitors and Xa factor inhibitors, and the direct thrombin inhibitors, such as Dapicarn, piperazaban, Edozapan, are effective and safe. Oral convenience, rapid effect, food and drug impact, no need for routine monitoring of coagulation and other advantages. In cardiovascular disease, drugs such as rivastaban have been approved for stroke prevention of atrial fibrillation and treatment of venous thrombosis. However, the application of new anticoagulants in acute coronary syndrome is still in the clinical trial stage. New oral anticoagulants also have some limitations, including short half-life, lack of anticoagulant effect monitoring methods, no drug-related bleeding of special antagonists, and at the same time, in liver and kidney dysfunction, cancer, etc. There is still a lack of clinical data on the safety of use in special populations such as pregnancy. In this paper, the progress of new oral anticoagulants in cardiovascular diseases is reviewed.
【学位授予单位】：重庆医科大学
【学位级别】：硕士
【学位授予年份】：2016
【分类号】：R54

【相似文献】